Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GR2304
- Development stage
- Unknown
- Lead developer
- Zhixiang Jintai
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GR2304 is a bispecific T-cell engager developed by Chongqing Zhixiang Jintai Biopharmaceutical (Genrix Bio). It is designed to target the PRAME (Preferentially Expressed Antigen in Melanoma) peptide-MHC complex on the surface of tumor cells while simultaneously binding to the CD3 receptor on T-cells. This dual binding facilitates the recruitment and activation of T-cells to specifically eliminate PRAME-expressing cancer cells. PRAME is a cancer-testis antigen that is highly expressed in various solid tumors and hematologic malignancies but has limited expression in normal tissues, making it a promising target for immunotherapy. GR2304 is currently being evaluated in Phase 1 clinical trials for the treatment of PRAME-positive advanced solid tumors.
- Other names
- CD3-pMHC (PRAME) bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)PRAME peptide–HLA complex
Beyond the preview
Go deeper on GR2304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GR2304.